Cargando…
Enantiopure Indolo[2,3-a]quinolizidines: Synthesis and Evaluation as NMDA Receptor Antagonists
Enantiopure tryptophanol is easily obtained from the reduction of its parent natural amino acid trypthophan (available from the chiral pool), and can be used as chiral auxiliary/inductor to control the stereochemical course of a diastereoselective reaction. Furthermore, enantiopure tryptophanol is u...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6272859/ https://www.ncbi.nlm.nih.gov/pubmed/27509489 http://dx.doi.org/10.3390/molecules21081027 |
_version_ | 1783377250653044736 |
---|---|
author | Pereira, Nuno A. L. Sureda, Francesc X. Pérez, Maria Amat, Mercedes Santos, Maria M. M. |
author_facet | Pereira, Nuno A. L. Sureda, Francesc X. Pérez, Maria Amat, Mercedes Santos, Maria M. M. |
author_sort | Pereira, Nuno A. L. |
collection | PubMed |
description | Enantiopure tryptophanol is easily obtained from the reduction of its parent natural amino acid trypthophan (available from the chiral pool), and can be used as chiral auxiliary/inductor to control the stereochemical course of a diastereoselective reaction. Furthermore, enantiopure tryptophanol is useful for the syntheses of natural products or biological active molecules containing the aminoalcohol functionality. In this communication, we report the development of a small library of indolo[2,3-a]quinolizidines and evaluation of their activity as N-Methyl d-Aspartate (NMDA) receptor antagonists. The indolo[2,3-a]quinolizidine scaffold was obtained using the following key steps: (i) a stereoselective cyclocondensation of (S)- or (R)-tryptophanol with appropriate racemic δ-oxoesters; (ii) a stereocontrolled cyclization on the indole nucleus. The synthesized enantiopure indolo[2,3-a]quinolizidines were evaluated as NMDA receptor antagonists and one compound was identified to be 2.9-fold more potent as NMDA receptor blocker than amantadine (used in the clinic for Parkinson’s disease). This compound represents a hit compound for the development of novel NMDA receptor antagonists with potential applications in neurodegenerative disorders associated with overactivation of NMDA receptors. |
format | Online Article Text |
id | pubmed-6272859 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-62728592018-12-28 Enantiopure Indolo[2,3-a]quinolizidines: Synthesis and Evaluation as NMDA Receptor Antagonists Pereira, Nuno A. L. Sureda, Francesc X. Pérez, Maria Amat, Mercedes Santos, Maria M. M. Molecules Communication Enantiopure tryptophanol is easily obtained from the reduction of its parent natural amino acid trypthophan (available from the chiral pool), and can be used as chiral auxiliary/inductor to control the stereochemical course of a diastereoselective reaction. Furthermore, enantiopure tryptophanol is useful for the syntheses of natural products or biological active molecules containing the aminoalcohol functionality. In this communication, we report the development of a small library of indolo[2,3-a]quinolizidines and evaluation of their activity as N-Methyl d-Aspartate (NMDA) receptor antagonists. The indolo[2,3-a]quinolizidine scaffold was obtained using the following key steps: (i) a stereoselective cyclocondensation of (S)- or (R)-tryptophanol with appropriate racemic δ-oxoesters; (ii) a stereocontrolled cyclization on the indole nucleus. The synthesized enantiopure indolo[2,3-a]quinolizidines were evaluated as NMDA receptor antagonists and one compound was identified to be 2.9-fold more potent as NMDA receptor blocker than amantadine (used in the clinic for Parkinson’s disease). This compound represents a hit compound for the development of novel NMDA receptor antagonists with potential applications in neurodegenerative disorders associated with overactivation of NMDA receptors. MDPI 2016-08-06 /pmc/articles/PMC6272859/ /pubmed/27509489 http://dx.doi.org/10.3390/molecules21081027 Text en © 2016 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Pereira, Nuno A. L. Sureda, Francesc X. Pérez, Maria Amat, Mercedes Santos, Maria M. M. Enantiopure Indolo[2,3-a]quinolizidines: Synthesis and Evaluation as NMDA Receptor Antagonists |
title | Enantiopure Indolo[2,3-a]quinolizidines: Synthesis and Evaluation as NMDA Receptor Antagonists |
title_full | Enantiopure Indolo[2,3-a]quinolizidines: Synthesis and Evaluation as NMDA Receptor Antagonists |
title_fullStr | Enantiopure Indolo[2,3-a]quinolizidines: Synthesis and Evaluation as NMDA Receptor Antagonists |
title_full_unstemmed | Enantiopure Indolo[2,3-a]quinolizidines: Synthesis and Evaluation as NMDA Receptor Antagonists |
title_short | Enantiopure Indolo[2,3-a]quinolizidines: Synthesis and Evaluation as NMDA Receptor Antagonists |
title_sort | enantiopure indolo[2,3-a]quinolizidines: synthesis and evaluation as nmda receptor antagonists |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6272859/ https://www.ncbi.nlm.nih.gov/pubmed/27509489 http://dx.doi.org/10.3390/molecules21081027 |
work_keys_str_mv | AT pereiranunoal enantiopureindolo23aquinolizidinessynthesisandevaluationasnmdareceptorantagonists AT suredafrancescx enantiopureindolo23aquinolizidinessynthesisandevaluationasnmdareceptorantagonists AT perezmaria enantiopureindolo23aquinolizidinessynthesisandevaluationasnmdareceptorantagonists AT amatmercedes enantiopureindolo23aquinolizidinessynthesisandevaluationasnmdareceptorantagonists AT santosmariamm enantiopureindolo23aquinolizidinessynthesisandevaluationasnmdareceptorantagonists |